NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a novel drug combo outperform standard chemo for lung cancer?
Disease control Not yet recruitingThis trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New cocktail therapy aims to tackle Drug-Resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted ther…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New lung cancer drug HB0025 faces off against standard therapy in major trial
Disease control Not yet recruitingThis Phase 3 trial will test whether a new drug called HB0025, combined with standard chemotherapy, works better than the current treatment tislelizumab plus chemotherapy for people with advanced nonsquamous non-small cell lung cancer. About 500 participants will be randomly assi…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC